Advanced search
Publication Cover
Journal of Hepatocellular Carcinoma Volume 10, 2023 - Issue
Submit an article Journal homepage
120
Views
0
CrossRef citations to date
0
Altmetric
CASE SERIES

The Extended Surgical Concepts for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors

Hsiao-Mei Hsu1 Department of Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan, TaiwanView further author information
,
Hsin-I Tsai2 Department of Anesthesiology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan;3 Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan;4 College of Medicine, Chang Gung University, Taoyuan, TaiwanView further author information
,
Wei-Chen Lee4 College of Medicine, Chang Gung University, Taoyuan, Taiwan;5 Division of General Surgery, Department of Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan, TaiwanORCID Iconhttps://orcid.org/0000-0002-8627-1324View further author information
ORCID Icon,
Chih-Chi Wang6 Division of General Surgery, Department of Surgery, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan;7 Division of General Surgery, Department of Surgery, Chiayi Chang Gung Memorial Hospital, Chiayi, TaiwanView further author information
,
Ming-Chin Yu3 Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan;4 College of Medicine, Chang Gung University, Taoyuan, Taiwan;8 Department of Surgery, New Taipei Municipal Tu-Cheng Hospital (Built and Operated by Chang Gung Medical Foundation), New Taipei City, TaiwanORCID Iconhttps://orcid.org/0000-0002-6980-7123View further author information
ORCID Icon,
Shi-Ming Lin4 College of Medicine, Chang Gung University, Taoyuan, Taiwan;9 Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Taoyuan, TaiwanView further author information
,
Chun-Yen Lin4 College of Medicine, Chang Gung University, Taoyuan, Taiwan;9 Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Taoyuan, TaiwanORCID Iconhttps://orcid.org/0000-0003-3007-3190View further author information
ORCID Icon,
Chi-Huan Wu4 College of Medicine, Chang Gung University, Taoyuan, Taiwan;9 Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Taoyuan, TaiwanView further author information
&
Chao-Wei Lee3 Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan;4 College of Medicine, Chang Gung University, Taoyuan, Taiwan;5 Division of General Surgery, Department of Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan, TaiwanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6853-4557View further author information
ORCID Icon show all
Pages 1873-1880 | Received 01 Sep 2023, Accepted 18 Oct 2023, Published online: 24 Oct 2023

References

  • Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.21262
  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
  • Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. doi:10.1038/s41572-020-00240-3
  • Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
  • Department of Health ROC: statistics of cause of death in Taiwan 2020. Executive Yuan, Republic of China; 2021.
  • Department of Health ROC: statistics of cause of death in Taiwan 2021. Executive Yuan, Republic of China; 2022.
  • Zhou XD, Tang ZY, Yang BH, et al. Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer. 2001;91(8):1479–1486. doi:10.1002/1097-0142(20010415)91:8<1479::AID-CNCR1155>3.0.CO;2-0
  • Lee CW, Tsai HI, Yu MC, et al. A proposal for T1 subclassification in hepatocellular carcinoma: reappraisal of the AJCC 8th edition. Hepatol Int. 2022;16(6):1353–1367. doi:10.1007/s12072-022-10422-8
  • Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245–1255. doi:10.1016/S0140-6736(11)61347-0
  • Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. doi:10.1016/j.jhep.2021.11.018
  • Singal AG, Llovet JM, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023:4:1.
  • Kudo M. A New Era in systemic therapy for hepatocellular carcinoma: atezolizumab plus bevacizumab combination therapy. Liver Cancer. 2020;9(2):119–137. doi:10.1159/000505189
  • Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862–873. doi:10.1016/j.jhep.2021.11.030
  • Kudo M, Finn RS, Galle PR, et al. IMbrave150: efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in patients with Barcelona Clinic Liver Cancer stage b unresectable hepatocellular carcinoma: an exploratory analysis of the phase III study. Liver Cancer. 2022;11(1):1–13. doi:10.1159/000521374
  • Kudo M. Atezolizumab plus bevacizumab followed by curative conversion (ABC Conversion) in patients with unresectable, TACE-unsuitable intermediate-stage hepatocellular carcinoma. Liver Cancer. 2022;11(5):399–406. doi:10.1159/000526163
  • Kudo M. A novel treatment strategy for patients with intermediate-stage HCC who are not suitable for TACE: upfront systemic therapy followed by curative conversion. Liver Cancer. 2021;10(6):539–544. doi:10.1159/000519749
  • Kudo M, Aoki T, Ueshima K, et al. Achievement of complete response and drug-free status by atezolizumab plus bevacizumab combined with or without curative conversion in patients with transarterial chemoembolization-unsuitable, intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study. Liver Cancer. 2023;12(1):1–18. doi:10.1159/000528979
  • Wu JC, Huang YH, Chau GY, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol. 2009;51(5):890–897. doi:10.1016/j.jhep.2009.07.009
  • Lee MS, Ryoo BY, Hsu CH, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020;21(6):808–820. doi:10.1016/S1470-2045(20)30156-X
  • Kudo M, Zolota V, Tzelepi V. Changing the treatment paradigm for hepatocellular carcinoma using atezolizumab plus bevacizumab combination therapy. Cancers. 2021;14(1):13. doi:10.3390/cancers14010013
  • Kokudo T, Hasegawa K, Matsuyama Y, et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol. 2016;65(5):938–943. doi:10.1016/j.jhep.2016.05.044
  • Zhu AX, Abbas AR, de Galarreta MR, et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022;28(8):1599–1611. doi:10.1038/s41591-022-01868-2
  • Haber PK, Castet F, Torres-Martin M, et al. Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma. Gastroenterology. 2023;164(1):72–88.e18. doi:10.1053/j.gastro.2022.09.005

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.